<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Controlling chemotherapy-induced <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo>(CINV)is very important for the continuation of chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>CINV can significantly affect a patient's quality of life, leading to poor compliance with further chemotherapy treatment </plain></SENT>
<SENT sid="2" pm="."><plain>In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Eighty-eight patients were included in the efficacy analyses: 39 patients in the palonosetron group and 49 patients in the granisetron group </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of <z:hpo ids='HP_0002018'>nausea</z:hpo> in the granisetron group(Grade 1: 40 </plain></SENT>
<SENT sid="5" pm="."><plain>8%, Grade 2: 10 </plain></SENT>
<SENT sid="6" pm="."><plain>2% and Grade 3: 4 </plain></SENT>
<SENT sid="7" pm="."><plain>1%)was significantly higher than in the palonosetron group (Grade 1: 25 </plain></SENT>
<SENT sid="8" pm="."><plain>6% and Grade 2: 7 </plain></SENT>
<SENT sid="9" pm="."><plain>7%, p=0 </plain></SENT>
<SENT sid="10" pm="."><plain>0422) </plain></SENT>
<SENT sid="11" pm="."><plain>The incidence of <z:hpo ids='HP_0002013'>vomiting</z:hpo> and appetite loss in the granisetron group was not significantly higher than in the palonosetron group(p=0 </plain></SENT>
<SENT sid="12" pm="."><plain>2419, p=0 </plain></SENT>
<SENT sid="13" pm="."><plain>2648, respectively) </plain></SENT>
<SENT sid="14" pm="."><plain>This suggests that palonosetron exerts better efficacy against chemotherapy-induced <z:hpo ids='HP_0002018'>nausea</z:hpo> than granisetron in patients receiving mFOLFOX6 and FOLFIRI </plain></SENT>
<SENT sid="15" pm="."><plain>Information on such analyses is useful to promote the effectiveness of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy </plain></SENT>
</text></document>